Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study

BACKGROUND: The phase III ALEX study in patients with treatment-naive advanced anaplastic lymphoma kinase mutation-positive (ALK+) non-small-cell lung cancer (NSCLC) met its primary end point of improved progression-free survival (PFS) with alectinib versus crizotinib. Here, we present detailed cent...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Ann Oncol
Main Authors: Gadgeel, S, Peters, S, Mok, T, Shaw, A T, Kim, D W, Ou, S I, Pérol, M, Wrona, A, Novello, S, Rosell, R, Zeaiter, A, Liu, T, Nüesch, E, Balas, B, Camidge, D R
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2018
Teme:
Original articles
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6290889/
https://ncbi.nlm.nih.gov/pubmed/30215676
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdy405
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki